Sanj K. Patel - 07 Apr 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role: CHAIRMAN & CEO, Director
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol: KNSA
Transactions as of: 07 Apr 2025
Net transactions value: -$97,993
Form type: 4
Filing time: 09 Apr 2025, 16:44:13 UTC
Previous filing: 03 Apr 2025
Next filing: 05 May 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Ordinary Share	Options Exercise		+9,992	+11%		101,506	07 Apr 2025	Direct	F1
transaction	KNSA	Class A Ordinary Share	Tax liability	$97,993	-4,832	-4.8%	$20.28	96,674	07 Apr 2025	Direct
holding	KNSA	Class A Ordinary Share						109,795	07 Apr 2025	Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-9,992	-50%	$0.000000	9,991	07 Apr 2025	Class A Ordinary Share	9,992		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSs vesting on the yearly anniversary of the grant date, April 7, 2022.